{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:20:34Z","timestamp":1791109234077,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1136\/ard.2007.083683","type":"journal-article","created":{"date-parts":[[2008,2,2]],"date-time":"2008-02-02T01:25:42Z","timestamp":1201915542000},"page":"1697-1701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study"],"prefix":"10.1016","volume":"67","author":[{"given":"B J F","family":"van den Bemt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A A","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G F","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y A","family":"Hekster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P L C M","family":"van Riel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Benraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G J","family":"Wolbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F H J","family":"van den Hoogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.083683_bib1","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083683_bib2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2007.083683_bib3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis.","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.083683_bib4","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2006.065995","article-title":"Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.","volume":"66","author":"Rahman","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083683_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/rheumatology\/keh494","article-title":"A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg\/kg every 8 weeks can be effective: a Belgian prospective study.","volume":"44","author":"Durez","year":"2005","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.083683_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.2003.015933","article-title":"Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.","volume":"63","author":"Sidiropoulos","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083683_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/ard.2003.010967","article-title":"Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.","volume":"36","author":"van Vollenhoven","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083683_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/rheumatology\/41.6.638","article-title":"Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF\u03b1.","volume":"41","author":"den Broeder","year":"2002","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.083683_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/rheumatology\/kel173","article-title":"Titration of infliximab in rheumatoid arthritis patients based on response patterns.","volume":"46","author":"Flendrie","year":"2007","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.083683_bib10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/art.22718","article-title":"Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis.","volume":"56","author":"van der Bijl","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083683_bib11","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies.","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/ard.2007.083683_bib12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083683_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease.","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.083683_bib14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.2004.030452","article-title":"Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.","volume":"64","author":"Wolbink","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083683_bib15","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor \u03b1 inhibitor infliximab.","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083683_bib16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2165\/00003495-200059060-00010","article-title":"Infliximab: a review of its use in the management of rheumatoid arthritis.","volume":"59","author":"Markham","year":"2000","journal-title":"Drugs"},{"key":"10.1136\/ard.2007.083683_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083683_bib18","first-page":"31","article-title":"Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.","volume":"33","author":"Haraoui","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083683_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083683_bib20","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.","volume":"41","author":"van Gestel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083683_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard.2005.049858","article-title":"Relationship between serum adalimumab levels, incidence of human anti-human antibodies (HAHAS) and clinical response to adalimumab in patients with rheumatoid arthritis (RA).","volume":"65","author":"Bartelds","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083683_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","article-title":"Clinical pharmacokinetics of TNF antagonists: how do they differ?","volume":"34","author":"Nestorov","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl II","key":"10.1136\/ard.2007.083683_bib23","first-page":"p325","article-title":"The drug survival of adalimumab compared to etanercept and infliximab in treatment of patients with rheumatoid arthritis in daily clinical practice.","volume":"65","author":"Kievit","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724426897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724426897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.083683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:52:55Z","timestamp":1737359575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724426897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0003496724426897"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.083683","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.083683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}